Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small…
Source:Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC
Friday, January 30, 2015
Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment